Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 09, 2024

Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Refractory EGFR-Mutated NSCLC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR-mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study
J. Clin. Oncol 2024 Jun 10;[EPub Ahead of Print], NB Leighl, H Akamatsu, SM Lim, Y Cheng, AR Minchom, ME Marmarelis, RE Sanborn, J Chih-Hsin Yang, B Liu, T John, B Massutí, AI Spira, SH Lee, J Wang, J Li, C Liu, S Novello, M Kondo, M Tamiya, E Korbenfeld, M Moskovitz, JY Han, M Alexander, R Joshi, E Felip, PJ Voon, P Danchaivijitr, PC Hsu, FJ Silva Melo Cruz, T Wehler, L Greillier, E Teixeira, D Nguyen, JK Sabari, A Qin, D Kowalski, MA Nahit Şendur, J Xie, D Ghosh, A Alhadab, N Haddish-Berhane, PL Clemens, P Lorenzini, RB Verheijen, M Gamil, JM Bauml, M Baig, A Passaro

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading